Education
About Us
Working with TipRanks
Follow Us
Calcimedica, Inc. (CALC)
:CALC
CALC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.45 - $6.27
Previous CloseN/A
Volume2.29K
Average Volume (3M)58.54K
Market Cap
$21.96M
Enterprise Value$26.50M
Total Cash (Recent Filing)$15.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
May 19, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding13,481,917
10 Day Avg. Volume26,667
30 Day Avg. Volume58,540
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$18.00Price Target Upside1004.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
CalciMedica News
PremiumCompany Announcements
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment
PremiumCompany Announcements
CalciMedica Announces Board Changes and New Appointment
---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe clinical benefits of Auxora, including the potential for reduced dialysis, mortality, and greater recovery of renal function, are expected to drive its adoption in the market.
Financial PerformanceCalciMedica announced 2024 full year financial results, posting EPS of ($1.22), compared to consensus of ($1.44).
Market OpportunityWith over 1 million patients in the AKI Auxora target market, there is anticipation of a significant market opportunity exceeding $10 billion.
Bears Say
Clinical TrialsEnrollment is ongoing in the Phase 2 portion of the CRSPA study in AIPT and the company expects to provide a study update in 2H25.
Debt FinancingManagement believes the recent March 2025 debt financing provides runway for ongoing operations into mid-2026.
EPS PerformanceCalciMedica announced 2024 full year financial results, posting EPS of ($1.22), which still reflects a negative earnings situation.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CALC FAQ
What was Calcimedica, Inc.’s price range in the past 12 months?
Calcimedica, Inc. lowest stock price was $1.45 and its highest was $6.26 in the past 12 months.
What is Calcimedica, Inc.’s market cap?
Calcimedica, Inc.’s market cap is $21.96M.
When is Calcimedica, Inc.’s upcoming earnings report date?
Calcimedica, Inc.’s upcoming earnings report date is May 19, 2025 which is in 33 days.
How were Calcimedica, Inc.’s earnings last quarter?
Calcimedica, Inc. released its earnings results on Mar 27, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.052.
Is Calcimedica, Inc. overvalued?
According to Wall Street analysts Calcimedica, Inc.’s price is currently Undervalued.
Does Calcimedica, Inc. pay dividends?
Calcimedica, Inc. does not currently pay dividends.
What is Calcimedica, Inc.’s EPS estimate?
Calcimedica, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Calcimedica, Inc. have?
Calcimedica, Inc. has 13,481,917 shares outstanding.
What happened to Calcimedica, Inc.’s price movement after its last earnings report?
Calcimedica, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went up 4.02%.
Which hedge fund is a major shareholder of Calcimedica, Inc.?
Currently, no hedge funds are holding shares in CALC
---
CalciMedica Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (1004.29% Upside)
$18.00 (1004.29% Upside)
Blogger Sentiment
Bullish
CALC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 300.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.31%
12-Months-Change
Fundamentals
Return on Equity
-121.42%
Trailing 12-Months
Asset Growth
62.45%
Trailing 12-Months
Company Description
Calcimedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
---
CALC Stock 12 Month Forecast
Average Price Target
$18.00
▲(1004.29% Upside)
Technical Analysis
Best Analysts Covering CALC
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-34.81%
reiterated a buy rating last month
Copying Leland Gershell's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -34.81% per trade.
---